Stay updated with breaking news from Jacobin pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jacobin Pharma announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the. ....
/PRNewswire/ Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor. ....